ITOS VS IGMS Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatility
PerformanceSentimentTechnicalsEarningsProfitVolatility

Performance

ITOS
10/100

ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.

IGMS
10/100

IGMS returned -81.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

ITOS
72/100

ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.

IGMS
68/100

IGMS had a bullish sentiment score of 68.02% across Twitter and StockTwits over the last 12 months. It had an average of 4.12 posts, 0.42 comments, and 0.47 likes per day.

Technicals

ITOS
14/100

ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

IGMS
50/100

IGMS receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

ITOS
10/100

ITOS has missed earnings 5 times in the last 20 quarters.

IGMS
67/100

IGMS has missed earnings 3 times in the last 20 quarters.

Profit

ITOS
31/100

Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.

IGMS
10/100

Out of the last 20 quarters, IGMS has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ITOS
40/100

ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

IGMS
43/100

IGMS has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

All score calculations are broken down here to help you make more informed investing decisions

iTeos Therapeutics, Inc. Common Stock Summary

Nasdaq / ITOS
Healthcare
Biotechnology
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

IGM Biosciences, Inc. Common Stock Summary

Nasdaq / IGMS
Healthcare
Biotechnology
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.